Find clinical trials for hidradenitis suppurativa. Search for hidradenitis suppurativa clinical trials in different cities and states across the United States.
Sponsor:
University of Minnesota
Location:
Code:
NCT06058520
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Fecal Microbiota - lyophilized
Placebo drug
Sponsor:
Boehringer Ingelheim
Location:
Code:
NCT06241573
Conditions
Hidradenitis Suppurativa (HS)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Spesolimab
Sponsor:
AbbVie
Location:
Code:
NCT05889182
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Placebo
Sponsor:
Joseph M. Still Research Foundation, Inc.
Location:
Code:
NCT05477225
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NovoSorb® BTM
Human Cadaveric Allograft
Sponsor:
Sanofi
Location:
Code:
NCT06028230
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
SAR444656 (KT-474)
Placebo
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06046729
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Eltrekibart
Placebo
Sponsor:
Aroa Biosurgery Limited
Location:
Code:
NCT05243966
Conditions
Abdominal Wound Dehiscence
Necrotizing Soft Tissue Infection
Lower Extremity Wound
Pilonidal Sinus
Anal Fistula
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Myriad Matrix™ and Myriad Morcells™
Clinical trials for Hidradenitis Suppurativa (HS) are research studies conducted to find new treatments or to evaluate the effectiveness and safety of existing treatments for HS. These trials offer insights that can lead to advancements in treatment methods, improvement in patient care, and even potential cures for this debilitating condition.
HS clinical trials specifically target the complexities of the disease, focusing on reducing the severity of symptoms, preventing flare-ups, and improving the quality of life for those affected. Despite ongoing research, HS remains a challenging condition to treat, highlighting the need for innovative clinical trials.
Clinical trials for Hidradenitis Suppurativa (HS) play a key role in developing new treatments and understanding this condition better. These trials are essential for obtaining regulatory approvals, making sure that any new treatment is safe for patients and effective in treating or managing HS.
HS clinical trials provide valuable information on how the disease progresses, the most effective management practices, and its impact on patients’ lives. This knowledge is crucial for creating comprehensive treatment plans that not just tackle the physical symptoms but also consider the psychological aspects of HS. Ultimately, these studies not only aim to find better treatments but also to increase awareness and understanding of HS, encouraging a more informed and supportive community for those affected.
Clinical trials for Hidradenitis Suppurativa (HS) encompass a wide array of studies, each with a distinct focus aimed at not only enhancing our understanding and treatment of the condition but also exploring various approaches to improve patient care. These include investigating new treatments, developing better diagnostic methods, identifying effective prevention strategies, and efforts to enhance the quality of life for those affected.
Treatment trials focus on testing new medications or finding new ways to use existing treatments for HS. This includes testing drugs that target specific inflammatory processes, using antibiotics to reduce infection risks, or evaluating surgical options to remove damaged tissue. The goal is to find more effective treatments with fewer side effects, potentially including drugs already on the market but not previously used for HS. These trials aim to improve treatment options for HS patients by identifying what works best.
Diagnostic studies aim to improve how HS is diagnosed, making it quicker and more accurate. This involves using genetic testing, advanced imaging techniques, and other non-invasive methods to identify the disease earlier. The goal is to reduce the time it takes to diagnose HS, allowing for earlier treatment. By finding reliable markers of the disease, these studies help in tailoring the diagnosis to each patient's condition, potentially leading to better management strategies.
Prevention trials look for ways to prevent HS from developing, especially in people at higher risk. These studies may explore how lifestyle changes, like diet adjustments or quitting smoking, could reduce the risk of developing HS. They also test whether certain medications can prevent HS symptoms in people who are genetically predisposed but have not yet shown symptoms. The aim is to find strategies that can stop the disease before it starts, focusing on early intervention and risk reduction.
Quality of life (QoL) studies investigate how to improve the daily lives of people with HS. This includes testing interventions for pain relief, reducing the appearance of scars, and addressing the psychological impacts of HS, such as anxiety and depression. These studies also examine the benefits of patient education, psychological support, and lifestyle counseling in helping patients manage their condition better. The goal is to develop a holistic care approach that not only treats the physical symptoms of HS but also supports the patient's mental and emotional well-being, improving their overall quality of life.
Interested in learning more about hidradenitis suppurativa (HS)? Read all about what HS is, what can cause it, how it's diagnosed, and more in our comprehensive guide!
Individuals interested in participating in Hidradenitis Suppurativa (HS) clinical trials must meet certain criteria to ensure both their safety and the integrity of the trial results. Generally, eligibility is based on having a confirmed diagnosis of HS. Most trials require participants to be of a certain age, typically 18 years or older, although some studies may include younger participants with parental consent.
Eligibility criteria may also consider the severity of the condition, overall health status, treatment history, and specific lifestyle factors. Participants must be able to give informed consent and comply with trial procedures.
Before joining a clinical trial for hidradenitis suppurativa (HS), participants undergo a screening to confirm their eligibility and are informed in detail about the trial's purpose, procedures, and potential risks and benefits. This ensures they make an informed decision to participate. Once enrolled, they receive baseline assessments before starting treatments, which may vary from new drugs to lifestyle interventions. Throughout the trial, their health and response to treatment are closely monitored, sometimes requiring them to keep a symptom diary.
After the treatment phase, participants undergo final evaluations to measure the effectiveness of the intervention, with some studies also conducting long-term follow-ups. Participation demands a significant time commitment and may involve frequent site visits. It's crucial to understand the costs covered by the trial and the balance between potential benefits and risks.
Enrolling in a clinical trial for hidradenitis suppurativa through our platform is a straightforward and user-friendly process. Here's how to get started: